GuidelineThe Journal of urology2017
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.
Guideline in The Journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 407 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Randomized Non-inferiority Multicenter Study of PLND Omission in Clinical NMIBC Undergoing Radical Cystectomy
Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer
Who cites it
407 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in people undergoing radical cystectomy.The Cochrane database of systematic reviews · 2026Pooled it
- Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.World journal of urology · 2024Pooled it
- Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.International urology and nephrology · 2024Pooled it
- Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.World journal of urology · 2023Pooled it
- Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database.Journal of radiation research · 2023Pooled it
- Simultaneous radical cystectomy and nephroureterectomy in the treatment of panurothelial carcinoma: a systematic review and single-arm meta-analysis.Frontiers in oncology · 2023Pooled it
- Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin for Muscle-Invasive Bladder Cancer Patients Followed by Selective Bladder Sparing Surgery: A Phase 2 Trial.Cancer research and treatment · 2026Trial
- Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.Cancer prevention research (Philadelphia, Pa.) · 2025Trial
- Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.European urology oncology · 2024Trial
- Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.European urology oncology · 2024Trial
- Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.European urology · 2023Trial
- Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.Cancer medicine · 2023Trial
- A narrative review of the state of urinary diversion: ileal conduit, neobladder, continent cutaneous, and cutaneous ureterostomy.Translational andrology and urology · 2026Review
- Long-term survival prognosis and risk stratification after radical cystectomy with Mainz Pouch II urinary diversion: a retrospective cohort study and prognostic model construction.Translational andrology and urology · 2026Article
- Concurrent radiosensitising regimens for bladder-preserving radiotherapy in non-metastatic muscle-invasive bladder cancer: a systematic review and structured evidence synthesis with exploratory network meta-analysis.International urology and nephrology · 2026Review
- The impact of intraoperative ureteral stent omission on postoperative complications during radical cystectomy.World journal of urology · 2026Article
- Bladder preservation vs. radical cystectomy for T2N0M0: trends and survival outcomes from SEER.World journal of urology · 2026Article
- Review
- Hemostatic Efficacy and Clinical Outcomes of Radiotherapy in Older Adult Patients With Advanced Bladder Cancer and Hematuria Unsuitable for Standard Treatment.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
347 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
14 authors.
Funding
Abstract
purposeThis multidisciplinary, evidence-based guideline for clinically non-metastatic muscle-invasive bladder cancer focuses on the evaluation, treatment and surveillance of muscle-invasive bladder cancer guided toward curative intent. MATERIALS AND
methodsA systematic review utilizing research from the Agency for Healthcare Research and Quality as well as additional supplementation by the authors and consultant methodologists was used to develop the guideline. Evidence-based statements were based on body of evidence strengths Grade A, B or C and were designated as Strong, Moderate and Conditional Recommendations with additional statements presented in the form of Clinical Principles or Expert Opinions.
resultsFor the first time for any type of malignancy, the American Urological Association, American Society of Clinical Oncology, American Society for Radiation Oncology and Society of Urologic Oncology have formulated an evidence-based guideline based on a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer. This document is designed to be used in conjunction with the associated treatment algorithm.
conclusionsThe intensity and scope of care for muscle-invasive bladder cancer should focus on the patient, disease and treatment response characteristics. This guideline attempts to improve a clinician's ability to evaluate and treat each patient, but higher quality evidence in future trials will be essential to improve level of care for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.